tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Foghorn Therapeutics initiated with a Buy at Stifel
PremiumThe FlyFoghorn Therapeutics initiated with a Buy at Stifel
1M ago
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
Premium
Ratings
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
2M ago
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
Premium
Company Announcements
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
2M ago
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
PremiumThe FlyFoghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
2M ago
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
Premium
Ratings
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
2M ago
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
Premium
Ratings
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
3M ago
Foghorn Therapeutics Advances in Precision Therapeutics
PremiumCompany AnnouncementsFoghorn Therapeutics Advances in Precision Therapeutics
4M ago
Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
Premium
Ratings
Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
5M ago
Foghorn Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Foghorn Therapeutics Reports Q2 2025 Financial Results
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100